GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [PSA] T2D is not what most of this community thinks it is — 65 comments in the full submission. View in context.
2.1k
c/t2dglp1·submitted 1 year ago by u/rasmus_kimani

[PSA] T2D is not what most of this community thinks it is

Discussionbranch of 6 comments

T2D is not what most of this community thinks it is — with the reasoning, because a rule without a reason gets ignored. The diabetes and obesity programmes are separate, with different populations and different primary endpoints. Reading a result across from one to the other is not a comparison. Incretin-based agents…

Read the full submission and all 65 comments →

This branch

6 comments, started 1 year ago
u/gentle_correctionnice about it113 points·1 year ago

A1c reflects average glycaemia over roughly the preceding three months, weighted towards the most recent weeks. It cannot show variability and it lags any change you make.

replysharereportpermalink
u/gentle_correctionMOD66 points·1 year ago·edited

Left up. It distinguishes the sensor data from the lab result, which most posts here do not.

replysharereportpermalink
u/neha_rahimi139 points·1 year ago

the diabetes trials report different endpoints from the obesity ones

replysharereportpermalink
u/gustav_lindholm84 points·1 year ago

the diabetes trials report different endpoints from the obesity ones

Adding the obvious one — bring the export, not the single number, to whoever manages this.

replysharereportpermalink
u/rasmus_kimani56 points·1 year ago

Push back: one sensor reading is not a data point worth acting on, especially in the first day of wear.

replysharereportpermalink
u/rasmus_kimaniOP0 points·1 year ago

Are you quoting a diabetes trial or an obesity one?

replysharereportpermalink

← back to the whole thread

About c/t2dglp1

Type 2 diabetes as the original indication: A1c trajectories, CGM traces, hypoglycaemia risk when stacked with sulfonylureas or insulin, metformin combinations, and why the weight-loss conversation sometimes drowns out the glycaemic one.

36kmembers
62submissions
Jun 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/t2dglp1
c/t2dglp1 rules
  1. Insulin and sulfonylurea interactions are a real hypo risk. Do not hand-wave them.
  2. Post A1c with units and the assay date.
  3. No medication-stopping advice. Ever.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/a1c_arcu/fasting_insulin_fu/gentle_correction
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →